Literature DB >> 1285653

Therapy with topical corticosteroids.

W Sterry1.   

Abstract

Therapy with topical corticosteroids has improved greatly in recent years due to both advanced understanding of their mode of action and awareness of their side effects, as well as newly developed derivatives with specifically designed pharmacological properties. Paradoxically, the fear of using corticosteroids has increased on the part of the public during the same period. Treatment of inflammatory or neoplastic skin disorders with topical corticosteroids can be both successful and safe only if certain points are clarified before it is begun. These include (a) specific diagnosis, (b) choice of strength of the compound needed for control of the disease, (c) time schedule for length of therapy and planned patient visits, and (d) choice of vehicle adequate to the skin lesion. Topical corticosteroids of different potency are available today; one can classify these into four groups (weak, medium, strong, very strong) and use them in a patient-tailored treatment. When large areas are to be treated, systemic side effects must be taken into consideration, and compounds that are degraded quickly after absorption are recommended. Finally, the corticophobia of many patients must be addressed by careful information to ensure compliance. Using these guidelines, treatment with corticosteroids is highly effective, easy to use by the patient, and allows a maximum of safety.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1285653     DOI: 10.1007/bf00638237

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  9 in total

1.  Lipocortin.

Authors:  R Flower
Journal:  Biochem Soc Trans       Date:  1989-04       Impact factor: 5.407

2.  Modulation of phospholipase A2 activity in human fibroblasts.

Authors:  E Solito; L Parente
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

3.  Percutaneous absorption of clobetasol propionate from novel ointment and cream formulations.

Authors:  S M Harding; S Sohail; M J Busse
Journal:  Clin Exp Dermatol       Date:  1985-01       Impact factor: 3.470

4.  An attempt to evaluate the relative clinical potencies of various diluted and undiluted proprietary corticosteroid preparations.

Authors:  J R Gibson; J Kirsch; C R Darley; C A Burke
Journal:  Clin Exp Dermatol       Date:  1983-09       Impact factor: 3.470

5.  An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations.

Authors:  J R Gibson; J M Kirsch; C R Darley; S G Harvey; C A Burke; M E Hanson
Journal:  Br J Dermatol       Date:  1984-07       Impact factor: 9.302

Review 6.  Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin.

Authors:  M W Greaves; R D Camp
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

7.  The Duhring chamber assay for corticosteroid atrophy.

Authors:  P J Frosch; E M Behrenbeck; K Frosch; E Macher
Journal:  Br J Dermatol       Date:  1981-01       Impact factor: 9.302

8.  Dependence of corticosteroid penetration on the vehicle.

Authors:  M K Polano; M Ponec
Journal:  Arch Dermatol       Date:  1976-05

9.  The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment.

Authors:  K S Ryatt; J W Feather; A Mehta; J B Dawson; J A Cotterill; R Swallow
Journal:  Br J Dermatol       Date:  1982-07       Impact factor: 9.302

  9 in total
  1 in total

1.  TOPICOP©: a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents.

Authors:  Leïla Moret; Emmanuelle Anthoine; Hélène Aubert-Wastiaux; Anne Le Rhun; Christophe Leux; Juliette Mazereeuw-Hautier; Jean-François Stalder; Sébastien Barbarot
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.